Graceway and Pfizer have entered into an acquisition and license agreement. Under the deal, Graceway will acquire the worldwide commercial rights for three investigational dermatological molecules from Pfizer, and the related transferred or licensed intellectual properties.
Graceway will acquire two molecules that target the treatment of oily skin and acne, an early stage Stearoyl CoA Desaturase 1 (SCD1) Inhibitor and a Cholesterol-Acyltransferase (ACAT) Inhibitor, currently in phase-II of development.
In addition, Graceway will also acquire an Activin-Like Kinase 5 (ALK-5) Inhibitor, currently in early pre-clinical development. The ALK-5 Inhibitor is an agent for the reduction of surgical and traumatic scar formation.
Parellel to this acquisition and license agreement, the companies also executed a Master Services and Supply agreement under which Pfizer has agreed to perform developmental and clinical services for these three molecules.
David Rosen, Head of Out Licensing for Pfizer, said: “We are extremely pleased about this agreement with Graceway as part of Pfizer’s plan to out license R&D programs that are no longer core to its strategy but could become important medicines for patients.”